Abstract
Systemic chemotherapy is the standard of care for metastatic colorectal cancer (CRC) (1). However, CRC can present with liver-limited or liver-dominant metastatic disease. This has generated many strategies aimed at specifically treating liver metastases, often in combination with systemic therapy. Some trials have shown a survival benefit with strategies incorporating hepatic intra-arterial infusion (HAI) chemotherapy with floxuridine (2). Most studies, however, have not shown a benefit of treatment with intra-arterial hepatic embolic therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
